A retrospective, observational study assessing the efficacy of treatment agents in generalised, therapy-refractory anti-acetylcholine receptor antibody (anti-AChR-ab)-mediated MG with an observation period of 24 months
Latest Information Update: 25 Apr 2022
At a glance
- Drugs Eculizumab (Primary) ; Rituximab (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
Most Recent Events
- 01 May 2022 Results published in the Journal of Neurology, Neurosurgery and Psychiatry
- 25 Apr 2022 New trial record